La regulación y financiación de los medicamentos biosimilares en la OCDE
Retorno social de la inversión en salud
Innovación y regulación en biomedicina: obligados a entenderse
The Impact of Severe Obesity on Healthcare Resource Utilisation in Spain
An estimate of the cost of administering intravenous biological agents in Spanish day hospitals
Social economic costs of type 1 diabetes mellitus in pediatric patients in Spain: CHRYSTAL observational study
Women with urinary incontinence in Spain: Health-related quality of life and the use of healthcare resources
Pharmacoeconomic assessment of Pegaspargase versus Asparaginase in acute lymphocytic leukemia
Newsrare 2. Registros de pacientes y medicamentos huérfanos
